Comparison of Drug-Coated Balloons vs Bare-Metal Stents in Patients With Femoropopliteal Arterial Disease

Drug-Coated Balloons With or Without Provisional Bare Metal Stenting in Femoropopliteal Disease: No Metal Left Behind?

“…10 Detection of residual stenosis, dissection detection, and determination of next therapeutic step were all given appropriate designations for the use of peripheral IVUS in the femoropopliteal segment. 8 The current analysis adds to the body of literature supporting the use of DCBs for femoropopliteal disease by demonstrating that long-term patency of complex lesions is possible with stand-alone DCB treatment. For future work, it will be important to understand how best to determine the need for stents after DCB, particularly, in the setting of nonflow-limiting dissection and residual stenosis.…”

“…The recently published patient-level pooled analysis of the IN.PACT SFA I/II and IN.PACT SFA Japan DCB trials, along with the Complete SE and DURABILITY II (The United States Study for Evaluating Endovascular Treatments of Lesions in the Superficial Femoral Artery and Proximal Popliteal by UsIng the Protege EverfLex Nitinol Stent System II) single-arm bare metal stent (BMS) trials, compared outcomes of 771 patients with femoropopliteal PAD using inverse probability of treatment weighting adjustment for demographics, baseline lesions, and procedural characteristics between patients treated with DCB versus BMS. 8 For all adjusted outcomes (12-month primary patency: 90.4% DCB, 80.9% BMS, P =0.007; 36-month clinically driven target lesion revascularization: 85.6% DCB, 73.7% BMS; P =0.001; and the cumulative incidence of 36-month major adverse events: 25.3% DCB, 38.8% BMS; P <0.001), there was a benefit for DCB over BMS. The current analysis adds to the growing evidence that many femoropopliteal lesions—even complex, long, and calcified lesions—can be treated with DCB therapy without a stent.…”

“…10 Detection of residual stenosis, dissection detection, and determination of next therapeutic step were all given appropriate designations for the use of peripheral IVUS in the femoropopliteal segment. 8…”

Drug-Coated Balloon versus Drug-Eluting Stent: The Debate of Leave Nothing Behind

“…41 A promising new analysis of four prospective multicenter studies was presented in November 2022 with the results published in the Journal of the American College of Cardiology (JACC) supporting the use of DCB over BMS. 44 The authors found DCB to have higher 12-month patency (90.4% DCB, 80.9% BMS, p ¼ 0.007), higher freedom from revascularization (85.6% DCB, 73.7% BMS, p ¼ 0.001), and to be safer, with lower incidence of major adverse events (25.3% DCB, 38.8% BMS, p < 0.001). The results address the lack of data specifically comparing DCB to BMS and suggest that DCB is a superior option to BMS for lesions that are amenable to either intervention.…”

JET+PCB strategy in the treatment of superficial femoral artery occlusion: a case report

“…Отношения и деятельность: все авторы заявляют об отсутствии потенциального конфликта интересов, требующего раскрытия в данной статье. сегмента) [6]. Исследования были направлены на изучение отдаленных результатов лечения ПБА, первое из которых проводилось с применением баллона с лекарственным покрытием и без последующей имплантации стента (PCB), второе -с имплантацией голометаллического стента (BMS) [6].…”